查看购物车
  • Traditional Chinese
  • English
  • Japanese
全球非转移性前列腺癌市场：区域与国家分析与预测（2025-2035）
市场调查报告书
商品编码
1764708

全球非转移性前列腺癌市场：区域与国家分析与预测（2025-2035）

Non-metastatic Prostate Cancer Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 100 Pages | 商品交期: 1-5个工作天内

价格

非转移性前列腺癌市场的主要成长要素之一是对分子标靶治疗的需求不断增加，尤其是针对非转移性去势抗性前列腺癌 (nmCRPC)。

随着前列腺癌的进展，需要更有效、更个人化的治疗方法，尤其是对于那些对雄性激素剥夺疗法 (ADT) 等标准荷尔蒙疗法有抗药性的高风险患者。由于Enzalutamide(Xtandi) 和阿帕鲁胺 (Erleada) 等雄性激素受体抑制剂在延缓转移和提高存活率方面的成功，对此类治疗的需求激增。

此外，PSA检测和多参数MRI等早期诊断技术的进步，以及人们对摄护腺癌认识的提高，有助于早期发现非转移性摄护腺癌。早期诊断使我们能够迅速启动创新治疗，从而刺激了治疗需求的成长。基于基因检测和生物标记的精准医疗的广泛应用，也使得每位患者都能获得个人化治疗，进一步加速了市场的成长。

总体而言，对更先进、毒性更小、更有效的治疗方法、早期发现和意识提升的需求正在强力推动非转移性前列腺癌市场的扩张。

然而，市场发展仍面临诸多挑战。其中一个主要挑战是先进治疗方法的高成本。雄激素受体抑制剂（例如Enzalutamide和阿帕鲁胺）以及免疫疗法和分子标靶疗法等较新的治疗方法价格昂贵，对于没有全面保险的患者来说难以获得。这些昂贵的疗法也给整个医疗保健系统带来了沉重的财务负担，使其难以推广应用，尤其是在医疗资源有限的开发中国家。

除了成本障碍外，另一个重大挑战是抗治疗性。儘管Enzalutamide和阿帕鲁胺等药物已显示出对非转移性去势抗性前列腺癌 (nmCRPC) 的高效治疗，但许多患者在长期使用后会产生抗药性。抗药性会增加癌症进展的风险，迫使医生考虑替代疗法和更具侵入性的干预措施。然而，这些替代疗法并非总是有效，在某些情况下，选择有限。儘管持续进行去势治疗，去势抗性仍然是前列腺癌长期治疗中最严峻的挑战之一。

此外，诊断技术也存在限制。儘管多参数磁振造影（MRI）和基因检测等技术取得了进步，但前列腺癌的早期阶段仍然难以检测。此外，广泛使用的PSA检测特异性有限，并且可能产生假阳性和假阴性。这可能导致误诊或延误诊断，从而阻碍制定合适的治疗方案。

最后，目前治疗方法（尤其是雄性激素剥夺疗法和化疗）的副作用持续显着影响患者的生活品质。疲劳、性功能障碍、骨质疏鬆症和心血管风险等问题使许多患者难以接受长期治疗，并可能导致治疗依从性不佳，进一步加剧了非转移性前列腺癌的治疗难度。

本报告调查了全球非转移性前列腺癌市场，并总结了主要趋势、市场影响因素分析、法律制度、技术和专利分析、临床试验趋势、市场规模趋势和预测、各个细分市场、地区/主要国家的详细分析、竞争格局和主要企业的概况。

目录

执行摘要

第一章全球非转移性前列腺癌市场：产业展望

  • 市场趋势
  • 法律规范
  • 流行病学分析
  • 临床试验分析
  • 市场动态
    • 影响分析
    • 市场驱动因素
    • 市场挑战
    • 市场机会

2. 全球非转移性前列腺癌市场（按地区）

  • 北美洲
    • 主要发现
    • 市场动态
    • 市场规模及预测
  • 欧洲
    • 主要发现
    • 市场动态
    • 市场规模及预测
  • 亚太地区
    • 主要发现
    • 市场动态
    • 市场规模及预测

3. 全球非转移性前列腺癌市场：竞争格局与公司概况

  • 关键策略和发展
    • M&A
    • 协同活动
    • 业务扩展和资金筹措
    • 产品发布和核准
    • 其他活动
  • 公司简介
    • Johnson & Johnson (Janssen Pharmaceuticals)
    • Astellas Pharma
    • Bristol-Myers Squibb
    • Pfizer Inc.
    • Merck & Co.
    • Bayer AG
    • Sanofi
    • Clovis Oncology
    • AstraZeneca
    • AbbVie Inc.

第四章调查方法

Product Code: BHL3085SA

Global Non-metastatic Prostate Cancer Market, Analysis and Forecast: 2025-2035

Non-metastatic prostate cancer refers to a stage of prostate cancer where the disease remains confined to the prostate gland and has not spread to other parts of the body. This form of cancer is often diagnosed at an early stage through methods such as prostate-specific antigen (PSA) testing, digital rectal exams (DRE), and biopsy. Non-metastatic prostate cancer is typically classified as Stage I or Stage II in the TNM (Tumor, Node, Metastasis) staging system, where the tumor is localized within the prostate and there is no evidence of spread to nearby lymph nodes or distant organs. While the cancer may cause a slight or moderate rise in PSA levels, it is often still manageable with localized treatments. Common treatment options include active surveillance for less aggressive cases, radical prostatectomy (surgical removal of the prostate), or radiation therapy. In high-risk cases, androgen deprivation therapy (ADT) may be used to lower testosterone levels and prevent cancer progression. With early detection and appropriate treatment, non-metastatic prostate cancer generally has a favorable prognosis, but management varies depending on factors such as cancer aggressiveness, patient age, and overall health.

One of the key drivers of the Non-metastatic Prostate Cancer market is the increasing demand for targeted therapies, particularly for non-metastatic castration-resistant prostate cancer (nmCRPC). As prostate cancer evolves, particularly in high-risk patients who develop resistance to standard hormonal therapies like androgen deprivation therapy (ADT), there is a growing need for more effective and personalized treatment options. The success of androgen receptor inhibitors, such as Enzalutamide (Xtandi) and Apalutamide (Erleada), in delaying metastasis and improving survival rates has created a significant demand for such therapies.

Additionally, the rising awareness of prostate cancer, coupled with advancements in early diagnostic methods like PSA testing and multiparametric MRI, has led to earlier detection of non-metastatic prostate cancer. This early detection allows for timely intervention with innovative therapies, which are contributing to the growing demand for treatment options. Moreover, the increasing adoption of precision medicine, based on genetic testing and biomarkers, is enabling more personalized treatments that are tailored to the specific needs of each patient, further accelerating Non-metastatic prostate cancer market growth.

Overall, the demand for more advanced, less toxic, and more effective treatments for non-metastatic prostate cancer, along with early detection and increased awareness, is driving the expansion of the non-metastatic prostate cancer market.

Despite the growth of the Non-metastatic Prostate Cancer market, several challenges continue to hinder its progress. One of the primary challenges is the high cost of advanced therapies. Treatments such as androgen receptor inhibitors (e.g., Enzalutamide and Apalutamide) and newer therapies like immunotherapies or targeted treatments can be extremely expensive, making them less accessible for many patients, especially those without comprehensive insurance coverage. This high cost can also place a significant burden on healthcare systems, limiting widespread adoption, particularly in developing countries or regions with limited access to advanced medical care.

In addition to the cost barrier, another major challenge is treatment resistance. While therapies like Enzalutamide and Apalutamide have shown effectiveness in non-metastatic castration-resistant prostate cancer (nmCRPC), patients may eventually develop resistance to these treatments over time. This can lead to disease progression, forcing physicians to seek alternative therapies or more aggressive interventions, which may not always be available or as effective. The development of castration-resistant prostate cancer despite ongoing androgen deprivation therapy remains one of the most significant hurdles in the long-term management of prostate cancer.

Furthermore, there are limitations in diagnostic tools. Despite advances in imaging technologies like multiparametric MRI and genetic testing, early-stage prostate cancer is still difficult to detect in some cases. PSA testing, while widely used, has limitations in specificity, leading to false positives and false negatives, which can cause delays in accurate diagnosis and treatment planning.

Finally, side effects of current treatments, especially androgen deprivation therapy and chemotherapy, continue to affect patient quality of life. Issues like fatigue, sexual dysfunction, osteoporosis, and cardiovascular risks can make long-term adherence to treatment challenging for many patients, further complicating the management of non-metastatic prostate cancer.

Together, these factors present significant challenges in the Non-metastatic Prostate Cancer market, requiring continued innovation in both treatment options and diagnostic tools to overcome these barriers and improve patient outcomes.

The global Non-metastatic Prostate Cancer market is highly competitive, with several leading companies driving innovation and market growth, such as Johnson & Johnson (Janssen Pharmaceuticals), Astellas Pharma, Bristol-Myers Squibb, Pfizer Inc., Merck & Co., Bayer, Sanofi, Clovis Oncology, AstraZeneca, AbbVie, and Boehringer Ingelheim.

These companies are at the forefront of developing and commercializing treatments for non-metastatic prostate cancer, particularly non-metastatic castration-resistant prostate cancer (nmCRPC). Through next-generation androgen receptor inhibitors like Erleada (apalutamide) and Xtandi (enzalutamide), as well as androgen deprivation therapies and PARP inhibitors, they are offering innovative solutions to slow disease progression, delay metastasis, and improve survival rates.

With increased research investments and advancements in precision medicine, these companies are exploring new biomarkers, novel treatment combinations, and immunotherapies to provide more effective therapies tailored to individual patient needs. As global awareness and screening rates for prostate cancer rise, these companies continue to shape the landscape of non-metastatic prostate cancer treatment and contribute to the non-metastatic prostate cancer market's rapid growth.

Non-Metastatic Prostate Cancer Market Segmentation:

Segmentation 1: by Region

  • North America
  • Europe
  • Asia-Pacific

The global Non-metastatic Prostate Cancer market is undergoing significant transformation, fueled by emerging trends that are reshaping the landscape of prostate cancer treatment. One of the key trends is the growing focus on precision medicine, where advancements in genomic testing and biomarker profiling are allowing healthcare providers to tailor treatments based on the specific genetic makeup of a patient's cancer.

This approach is leading to the development of targeted therapies, such as Enzalutamide (Xtandi) and Apalutamide (Erleada), which are more effective, and less toxic compared to traditional therapies. In addition, the use of combination therapies is becoming more prevalent, as treatments like androgen receptor inhibitors are being combined with chemotherapy, immunotherapy, and radiation therapy to enhance effectiveness and address resistance.

Furthermore, the continued advancements in diagnostic technologies, such as multiparametric MRI and liquid biopsy, are enabling earlier and more accurate detection of non-metastatic prostate cancer, allowing for timely intervention. As global awareness of prostate cancer increases and screening programs become more widespread, more men are being diagnosed at earlier stages, driving demand for innovative therapies. Together, these trends are not only transforming how non-metastatic prostate cancer is treated but also expanding the non-metastatic prostate cancer market and improving patient outcomes.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Non-metastatic Prostate Cancer Market: Industry Outlook

  • 1.1 Introduction
  • 1.2 Market Trends
  • 1.3 Regulatory Framework
  • 1.4 Epidemiology Analysis
  • 1.5 Clinical Trial Analysis
  • 1.6 Market Dynamics
    • 1.6.1 Impact Analysis
    • 1.6.2 Market Drivers
    • 1.6.3 Market Challenges
    • 1.6.4 Market Opportunities

2. Global Non-metastatic Prostate Cancer Market (Region), ($Billion), 2023-2035

  • 2.1 North America
    • 2.1.1 Key Findings
    • 2.1.2 Market Dynamics
    • 2.1.3 Market Sizing and Forecast
      • 2.1.3.1 North America Non-metastatic Prostate Cancer Market, by Country
        • 2.1.3.1.1 U.S.
  • 2.2 Europe
    • 2.2.1 Key Findings
    • 2.2.2 Market Dynamics
    • 2.2.3 Market Sizing and Forecast
      • 2.2.3.1 Europe Non-metastatic Prostate Cancer Market, by Country
        • 2.2.3.1.1 Germany
        • 2.2.3.1.2 U.K.
        • 2.2.3.1.3 France
        • 2.2.3.1.4 Italy
  • 2.3 Asia Pacific
    • 2.3.1 Key Findings
    • 2.3.2 Market Dynamics
    • 2.3.3 Market Sizing and Forecast
      • 2.3.3.1 Asia Pacific Non-metastatic Prostate Cancer Market, by Country
        • 2.3.3.1.1 China
        • 2.3.3.1.2 Japan

3. Global Non-metastatic Prostate Cancer Market: Competitive Landscape and Company Profiles

  • 3.1 Key Strategies and Development
    • 3.1.1 Mergers and Acquisitions
    • 3.1.2 Synergistic Activities
    • 3.1.3 Business Expansions and Funding
    • 3.1.4 Product Launches and Approvals
    • 3.1.5 Other Activities
  • 3.2 Company Profiles
    • 3.2.1 Johnson & Johnson (Janssen Pharmaceuticals)
      • 3.2.1.1 Overview
      • 3.2.1.2 Top Products / Product Portfolio
      • 3.2.1.3 Top Competitors
      • 3.2.1.4 Target Customers/End-Users
      • 3.2.1.5 Key Personnel
      • 3.2.1.6 Analyst View
    • 3.2.2 Astellas Pharma
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products / Product Portfolio
      • 3.2.2.3 Top Competitors
      • 3.2.2.4 Target Customers/End-Users
      • 3.2.2.5 Key Personnel
      • 3.2.2.6 Analyst View
    • 3.2.3 Bristol-Myers Squibb
      • 3.2.3.1 Overview
      • 3.2.3.2 Top Products / Product Portfolio
      • 3.2.3.3 Top Competitors
      • 3.2.3.4 Target Customers/End-Users
      • 3.2.3.5 Key Personnel
      • 3.2.3.6 Analyst View
    • 3.2.4 Pfizer Inc.
      • 3.2.4.1 Overview
      • 3.2.4.2 Top Products / Product Portfolio
      • 3.2.4.3 Top Competitors
      • 3.2.4.4 Target Customers/End-Users
      • 3.2.4.5 Key Personnel
      • 3.2.4.6 Analyst View
    • 3.2.5 Merck & Co.
      • 3.2.5.1 Overview
      • 3.2.5.2 Top Products / Product Portfolio
      • 3.2.5.3 Top Competitors
      • 3.2.5.4 Target Customers/End-Users
      • 3.2.5.5 Key Personnel
      • 3.2.5.6 Analyst View
    • 3.2.6 Bayer AG
      • 3.2.6.1 Overview
      • 3.2.6.2 Top Products / Product Portfolio
      • 3.2.6.3 Top Competitors
      • 3.2.6.4 Target Customers/End-Users
      • 3.2.6.5 Key Personnel
      • 3.2.6.6 Analyst View
    • 3.2.7 Sanofi
      • 3.2.7.1 Overview
      • 3.2.7.2 Top Products / Product Portfolio
      • 3.2.7.3 Top Competitors
      • 3.2.7.4 Target Customers/End-Users
      • 3.2.7.5 Key Personnel
      • 3.2.7.6 Analyst View
    • 3.2.8 Clovis Oncology
      • 3.2.8.1 Overview
      • 3.2.8.2 Top Products / Product Portfolio
      • 3.2.8.3 Top Competitors
      • 3.2.8.4 Target Customers/End-Users
      • 3.2.8.5 Key Personnel
      • 3.2.8.6 Analyst View
    • 3.2.9 AstraZeneca
      • 3.2.9.1 Overview
      • 3.2.9.2 Top Products / Product Portfolio
      • 3.2.9.3 Top Competitors
      • 3.2.9.4 Target Customers/End-Users
      • 3.2.9.5 Key Personnel
      • 3.2.9.6 Analyst View
    • 3.2.10 AbbVie Inc.
      • 3.2.10.1 Overview
      • 3.2.10.2 Top Products / Product Portfolio
      • 3.2.10.3 Top Competitors
      • 3.2.10.4 Target Customers/End-Users
      • 3.2.10.5 Key Personnel
      • 3.2.10.6 Analyst View

4. Research Methodology

List of Figures

  • Figure: Global Non-metastatic Prostate Cancer Market (by Region), $Billion, 2024 and 2035
  • Figure: Global Non-metastatic Prostate Cancer Market Key Trends, Analysis

List of Tables

  • Table: Global Non-metastatic Prostate Cancer Market Dynamics, Impact Analysis
  • Table: Global Non-metastatic Prostate Cancer Market (by Region), $Billion, 2024-2035